ETFIQData as of Nov 19, 2026. · etfiq.com/funds/pph

PPH Fact Sheet: VanEck Pharmaceutical ETF

Share
$114.85
close, Nov 20, 2026

Over the year to Nov 19, 2026, PPH returned +18.4% in total and charged 0.36% a year.

1-year total return
+19.2%
to Nov 20, 2026
Expense ratio
0.36%
a year
Net assets
$1.0bn
on Nov 19, 2026

Growth of $10,000, 1 year

PPH $11,835 +18.4% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−0.6%
3 months−1.2%
Year to date+13.2%
1 year+19.2%
3 years+56.7%
5 years+70.0%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Eli Lilly & Co22.99%
Merck & Co Inc11.58%
Novo Nordisk A/S5.46%
Mckesson Corp5.13%
Pfizer Inc4.74%
Cencora Inc4.54%
Teva Pharmaceutical Industries Ltd4.40%
Bristol-Myers Squibb Co4.33%
Gsk Plc4.23%
Abbvie Inc3.74%

PPH top ten by weight, 71.1% of the fund, of its 25 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Equity fund · Tracks the MVIS US Listed Pharmaceutical 25 Index · Benchmark Its own holdings, as of Nov 19, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, PPH Fact Sheet: VanEck Pharmaceutical ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/pph/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/pph.